Daiichi Sankyo moves Factor Xa drug to Ph III
Japan's Daiichi Sankyo has moved edoxaban into Phase III clinical trials, making it the only Factor Xa inhibitor in a dose-ranging study conducted in the treatment of atrial fibrillation.
In the new multicenter, double-blind, randomized study, around 16,500 patients will be assigned to one of three treatment groups: 30mg edoxaban once daily, 60mg edoxaban once daily and warfarin. Patients in the control arm will receive warfarin once a day, with the dosage adjusted so that the coagulation parameters lie within a certain target range.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze